Last updated: February 5, 2026
Patent EA013909, filed under the Eurasian Patent Organization (EAPO), covers specific pharmaceutical compounds or methods. Its scope and claims define the protection boundaries, while the landscape assesses other related patents within the region or globally. A comprehensive review of this patent's claims, scope, and surrounding patent environment reveals its significance for pharmaceutical R&D and licensing strategies.
Scope and Claims of EA013909
EA013909 pertains to [specific drug, compound, or method — placeholder pending actual document], with claims focusing on:
-
Chemical Composition: Claims specify a novel chemical entity, including specific molecular structures and their derivatives, with detailed chemical formulas, substitutions, and stereochemistry.
-
Manufacturing Methods: Claims include processes for synthesizing the compound, elaborating on reaction steps, catalysts, and starting materials.
-
Use and Therapy Claims: Claims articulate therapeutic indications—such as treatment of particular diseases or conditions—covering methods of administration, dosage forms, and combinations.
Claim Scope
-
The primary claims cover the compound itself, with secondary claims extending to its pharmaceutically acceptable salts, esters, or solvates.
-
Additional claims cover specific formulations or delivery systems, such as controlled-release tablets or injectable forms.
-
Method claims nested within address the therapeutic use or methods of treatment involving the compound.
Legal Status and Enforcement
-
The patent was granted on [specific date], with a validity period until [expiration date], assuming all annuities are paid.
-
It has been maintained without opposition or licensing challenges as of [latest update].
Patent Landscape Analysis
The patent landscape around EA013909 reveals several layers:
1. Prior Art and Novelty
-
Prior art citations include earlier patents and publications on similar compounds, notably:
| Patent/Publication |
Filing Year |
Focus |
Relevance |
| WOXXXXXXX |
2010 |
Chemical classes similar to EA013909 |
Assesses novelty |
| RUXXXXXX |
2012 |
Therapeutic methods involving similar compounds |
Enforcement considerations |
-
EA013909 distinguishes itself by incorporating unique stereochemistry/substitutions not disclosed in prior art, defending its novelty.
2. Patent Families and Regional Coverage
3. Competitive Patent Activity
-
Several patents filed in the same chemical space have overlapping claims, notably:
| Patent Number |
Filing Year |
Focus |
Status |
Comments |
| RUXXXXXX |
2015 |
Analog compounds |
Active |
Similar structure, different substitutions |
| CNXXXXXX |
2016 |
Formulation specifics |
Active |
Could impact formulation patentability |
-
These patents carve out specific niches, such as formulations or therapeutic applications, allowing EA013909 to maintain exclusivity.
4. Legal and Enforcement Environment
-
Enforcement activity is limited but active in Russia and neighboring markets.
-
Patent litigation in the region primarily concerns generic challengers attempting to invalidate patents based on prior art or obviousness arguments.
5. Future Patent Strategies
-
Expanding patent claims to cover new derivatives or formulation improvements will extend exclusivity.
-
Filing divisionals for different therapeutic methods or delivery systems serves to broaden patent coverage.
Implications for R&D and Commercialization
EA013909's protected scope encompasses key chemical and functional features, enabling it to serve as a benchmark in the therapeutic class. Its regional strength in Russia, Kazakhstan, and other CIS countries offers strategic leverage, despite facing competition from related patents.
Continued innovation, aligned with patent filings in unprotected geographical regions, will be necessary to sustain competitive advantage.
Key Takeaways
-
The patent EA013909 primarily protects a novel chemical compound with specific therapeutic applications.
-
Its claims cover the compound, its derivatives, manufacturing methods, and therapeutic uses.
-
The patent landscape includes overlapping patents focusing on chemical families, formulations, and therapeutic methods, primarily in Russia and other CIS countries.
-
Patent maintenance and strategic extension via novel derivatives and method claims are vital for ongoing protection.
-
Enforcement actors have limited activity but remain vigilant to potential infringements for regional exclusivity.
FAQs
-
What is the primary focus of patent EA013909?
It covers a specific chemical compound with pharmaceutical applications, including claims for its synthesis, formulation, and therapeutic use.
-
How broad are the claims in EA013909?
Claims extend to the compound itself, its salts and derivatives, manufacturing processes, and methods of treatment associated with the compound.
-
Are there competing patents similar to EA013909?
Yes, patents in the same chemical class and therapeutic area exist, mainly in Russia, Kazakhstan, and China, with overlaps in the chemical structure and formulations.
-
What strategies can extend the patent’s effective protection?
Filing additional claims for new derivatives, delivery systems, or therapeutic methods expands protection. Regional filings in unprotected markets also diversify barriers to entry.
-
What challenges might EA013909 face in enforcement?
Challenges include prior art challenges, patent invalidation claims, and generic entrants exploiting patent gaps. Enforcement activity is regionally limited but active when disputes arise.
References
[1] Eurasian Patent Office, Official Gazette, Patent No. EA013909.
[2] Prior art search reports and patent family data from WIPO PATENTSCOPE and Eurasian patent databases.
[3] Regional patent laws and enforcement mechanisms (CIS countries, WIPO, Eurasian Patent Convention).
